CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2, Subprotocol of DAY101 in Combination With Pimasertib for Patients With Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07121829
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:26.506027+00:00
Published At: 2025-08-14T00:00:00+00:00
Record Updated At: 2025-08-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma", "Solid Tumor", "Pilocytic Astrocytoma", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "MAP Kinase Family Gene Mutation", "RAS Mutation", "RAF Mutation", "MEK Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-14"
protocolSection.identificationModule.nctId: "NCT07121829"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2, Subprotocol of DAY101 in Combination With Pimasertib for Patients With Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.